Study on Fistuloplasty Using Flow Measurement Guidance
|ClinicalTrials.gov Identifier: NCT01643733|
Recruitment Status : Terminated (Not enough recruitment)
First Posted : July 18, 2012
Last Update Posted : March 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Failure on Dialysis Renal Failure||Device: Using Flow measurements to guide fistula angioplasty (Transonics)||Not Applicable|
This is a prospective randomized study. All intervention will be carried out by experienced radiologists in the two study centres.
At least fifty (50) consecutive subjects meeting the eligibility criteria, scheduled for angiographic assessment (with a view to PTA if necessary), will be invited to participate in the study. Subjects who consent will undergo their procedure, which will be performed by a qualified interventional radiology doctor (IRD). Patients will be randomly allocated to each group. All previous Transonics measurements will be available to the treating IRD. A target flow rate will be pre-decided in all patients in consultation with the nephrology service.
- All patients will undergo a fistulogram, a routine interventional Xray exam where radiocontrast media (RCM) is injected under X ray control to identify narrowings within the vessels. Significant lesions will be identified based on this exam. If a lesion is believed to be significant, the patient will be assigned to either arm of the study. The details of the disease present will be recorded as location and percentage stenosis.
- In the control arm, an initial Transonic measurement pre-treatment will be performed. The interventionalist will select the most significant lesion based on angiographic appearances and treat this lesion, which may require use of multiple balloons for the same lesion. At this point a Transonics measurement will be taken - Measurement A. The results will not be revealed to the interventionalist, who will proceed with the procedure as per their standard practice. A Transonics measurement will be taken after treatment of each of the significant lesions identified at the start of the exam. A post-procedural Transonics measurement (Measurement X) will also be taken, again the interventionalist will blinded as to this result. The appearances on completion angiography will be recorded as percentage stenosis remaining.
- In the Transonics arm, a pre-treatment Transonic measurement will be done. The lesions will be treated. Once Measurement A is obtained, the interventionalist will only be informed if the target value has been reached or not, they will not be told the actual value. This will be repeated for the treatment of each subsequent lesion, with the interventionalist being informed if the target had been reached, whilst being blinded as to the Transonics result, until the target has been achieved. The interventionalist will not pursue further treatment, regardless of the Transonics measurement, if he deems it would pose a greater risk of complication to the patient, than his/her standard practice. The appearances on completion angiography will be recorded as percentage stenosis remaining.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||Confirmation of Clinical Effectiveness and Safety of Use of Transonics in Determining Success of Intervention in Dialysis Fistulae|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||February 2017|
|Actual Study Completion Date :||February 2017|
Experimental: Transonics Arm
Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
Device: Using Flow measurements to guide fistula angioplasty (Transonics)
Transonics flow measurements in the fistula would be used to guide the fistula intervention
No Intervention: Control arm
Patient will undergo normal fistula intervention guided only by angiographic assessment
- Time to reintervention [ Time Frame: 6 months ]Time between intervention and the need for repeat intervention (based on standard dialysis screening systems).
- Effect of treatment on rate of change in Transonics flow measurements [ Time Frame: Baseline, 2 weeks, one, two three and 6 months ]Analysis of Transonics flow measurements obtained post intervention during the follow-up of six months
- Change in dialysis efficiency post treatment [ Time Frame: One month, 2, 3 and six months ]Comparison of Dialysis efficiency scores pre and post treatment
- Significance of stenoses as detected by Transonics, compared with angiography [ Time Frame: 1 day, ie.will be asessed immediately following intial intervention only. ]Assessment of extent to which using flow measurements can improve ability to detect hemodynamically significant stenoses.
- Nature of Procedure using Transonics versus Angiographic assessment [ Time Frame: Six months ]Comparison of procedures carried out between the group where Transonics flow measurements are used to guide intervention, versus the group where angiographic assessment is used.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01643733
|Royal Victoria Hospital|
|Montreal, Quebec, Canada, H3A 1A1|
|Montreal General Hospital|
|Montreal, Quebec, Canada, H3G 1A4|
|Principal Investigator:||David Valenti, MD||McGill University Health Centre/Research Institute of the McGill University Health Centre|
|Principal Investigator:||Louis Boucher, MD||McGill University Health Centre/Research Institute of the McGill University Health Centre|